The Company continues its progression towards a Nasdaq uplisting POMPANO BEACH, Fla., March 30, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has filed its audited consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2025. The financial statements are available for review in their entirety on the OTC Markets website here. With the publication of the audited consolidated financial statements, BioStem has taken another significant step toward a Nasdaq uplisting. “We are pleased to have published our audited financial statements for 2024 and 2025, which marks an important milestone for the Company. Along with...

Texas A&M University selected commercial IMSR plant for deployment at RELLIS campus U.S. Department of Energy selected both Terrestrial Energy reactor pilot and fuel-line pilot projects for advanced reactor programs NRC Accepted IMSR Principal Design Criteria Including Inherent Reactor Control Mechanisms Completed business combination, raising approximately $292 million in gross proceeds CHARLOTTE, N.C., March 30, 2026 (GLOBE NEWSWIRE) —  Terrestrial Energy Inc. (NASDAQ: IMSR) (“Terrestrial Energy” or “the Company”), a developer of small modular nuclear power plants using its Generation IV Integral Molten Salt Reactor (IMSR) technology, today announced its financial results for the fourth quarter and full year ended December 31, 2025. “The Company made strong progress in 2025 in key areas, regulatory readiness, fuel supply...

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter and year ended December 31, 2025. “The fourth quarter capped a year of important progress for PDS Biotech, marked by meaningful advances across our clinical programs, financial discipline, and intellectual property portfolio,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “Building on the...

STILLWATER, Okla., March 30, 2026 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (the Company), an emerging global leader in rare earths, today announced its financial and operational results for the fourth quarter and year ended December 31, 2025. Executive Commentary “2025 was the year that USA Rare Earth set the foundation to execute our integrated rare earth growth strategy,” said Barbara Humpton, CEO of USA Rare Earth. “We acquired the unique and internationally well-known metal and alloy making asset Less Common Metals, and we accelerated our progress toward mining development and magnet manufacturing. We are now rapidly developing a leading, globally integrated rare earth value chain that spans mining, processing, metal-making and magnet manufacturing, for the benefit of the U.S. and our allies. We are also attracting...

Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2025, and provided a business update. “This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and...

Deploys Capital into Cash-Flowing Manufacturing Businesses in Aerospace, Defense and IT Packaging Advances Dual Myostatin Assets Targeting Muscle Preservation in Potential Combination with GLP-1 TreatmentsNEWPORT BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (NASDAQ: ELAB) (“the Company,” “PMGC,” “we,” or “our”) today filed its Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2025 (“FYE 2025”), with the U.S. Securities and Exchange Commission (“SEC”). The Annual Report is available on the SEC’s website at www.sec.gov under the Company’s filings and on the Company’s investor relations website. A Year of Capital Allocation and Asset Growth Fiscal 2025 marked a year of disciplined capital deployment and balance sheet expansion.Total assets increased 43%, from approximately...

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies  KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study Strong financial position with $182.5 million in cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 Company to host conference call today at 8:00 a.m. ET WATERTOWN, Mass., March 30, 2026 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved,...

DALIAN, China, March 30, 2026 (GLOBE NEWSWIRE) — CBAK Energy Technology, Inc. (NASDAQ: CBAT) (“CBAK Energy,” or the “Company”), a leading lithium-ion battery manufacturer and electric energy solution provider in China, today reported its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial and Operational HighlightsFourth Quarter Consolidated Net Revenues achieved an explosive 131.8% year-over-year growth, reaching $58.80 million, compared to $25.37 million in the fourth quarter of 2024. This hyper-growth in the top line effectively decoupled from the temporary bottom-line pressures caused by ongoing capacity transitions. Fourth Quarter Net Revenues from Light Electric Vehicles (LEV) skyrocketed by 524.1% year-over-year to $12.92 million, compared...

– Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – – Current data package highlights well-tolerated long-term safety profile, broad-spectrum clinical activity, and favorable adherence for once daily brilaroxazine up to one year – – Initiation of RECOVER-2 registrational trial planned in mid-2026 – CUPERTINO, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31,...

Ci-joint le rapport financier annuel 2025AttachmentRapport Financier CRCAM 2025